These results provide compelling evidence that VEGFB and FLT1 may have potential as therapeutic targets in AD, but there remains a need to confirm these single nucleus transcriptomic results at the protein level and establish causality through experimental approaches. Here, FLT1 is linked to Alzheimer disease.